Thursday December 14th 2017

Fingolimod (Gilenya) licence extended

The European Medicines Agency (EMA) has approved an extension to the licensing of fingolimod (Gilenya), meaning that people can be prescribed the drug if they continue to have relapses despite treatment with at least one disease modifying therapy (previous this only applied after beta interferon treatment) . EMA Fingolimod (Gilenya) – A to Z of MS (Source: Multiple Sclerosis Trust)

See the original post: 

Fingolimod (Gilenya) licence extended

Leave a Comment

More from category

Cellular self-digestion process plays role in development of autoimmune diseases
Cellular self-digestion process plays role in development of autoimmune diseases

Autophagy allows cells to degrade and recycle their cellular components. Researchers at UZH have now demonstrated that [Read More]

Cambridge University Scientist Wins Innovation Prize for MS Research
Cambridge University Scientist Wins Innovation Prize for MS Research

/About-the-Society/News/Cambridge-University-Scientist-Wins-Innovation-Pri [Read More]

Study reveals how the body clock and time of day may influence autoimmune conditions
Study reveals how the body clock and time of day may influence autoimmune conditions

Insights into how the body clock and time of day influence immune responses are revealed today in a study published in [Read More]

Time of day affects severity of autoimmune disease
Time of day affects severity of autoimmune disease

(Trinity College Dublin) Immune responses and the regulation of autoimmunity are affected by the time of day when the [Read More]

Genes, Gut Bacteria, and Age Combine to Bring on MS-like Disease in Mice
Genes, Gut Bacteria, and Age Combine to Bring on MS-like Disease in Mice

/About-the-Society/News/Genes,-Gut-Bacteria,-and-Age-Combine-to-Bring-on-M [Read More]